PharmAthene Announces $3.9 Million Registered Direc... (e an offer to sell or the solicitation o...)

PharmAthene Announces $3.9 Million Registered Direct Offering

Date:7/20/2010

e an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the final prospectus supplement may be obtained, when available, at the Securities and Exchange Commission's website at http://www.sec.gov.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause a
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
2. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
3. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
4. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
5. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
6. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
7. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
8. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
9. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
10. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
11. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security

Post Your Comments:

(Date:6/18/2013)... Clara, CA (PRWEB) June 18, 2013 ... to standard size SEMs but have limited performance and ... lower resolution. Full size SEMs would normally provide better ... more knowledge to operate and have a higher cost ... address the gap between these two types of ...

(Date:6/18/2013)... 17, 2013) A million electric cars could be on ... with the help of research by the United States Department ... Waterloo. , Professor Zhongwei Chen is part of a team ... non-precious materials to replace the expensive platinum catalysts in fuel ... of fuel cells in vehicles is the cost of the ...

(Date:6/18/2013)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing, ... unaudited financial results for the fourth quarter and full ... Fourth Quarter of Fiscal 2013 Highlights ... 2013 increased by 33.3% to RMB133.0 million ($21.4 million) ...

(Date:6/18/2013)... In support of Swiss contributions to ... of Switzerland in New York is pleased to welcome ... PlanetSolar , to Manhattan. PlanetSolar is in New ... tour with scientists on board from the University of ... exclusively on energy from the sun and eliminates the ...

[0] Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes [0] US and Canadian researchers drive towards cheaper fuel cells for electric cars [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City

... Inc.,(NASDAQ: ISOT ) ("IsoTis"), an orthobiologics company, today ... it called to approve,the acquisition of IsoTis by Integra ... an agreement and plan of merger,dated as of August ... held at 9 a.m. Pacific time,today. An insufficient number ...

... Oct. 11 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... for 2007 after the market closes on Tuesday, November ... 4:30 p.m. EST,1:30 p.m. PST, on the company,s website. ... to the Company,s website at, http://www.cvt.com and go ...

... to be initiated by end of 2007 -, ... BIIB ) and PDL BioPharma, Inc. (PDL) (Nasdaq: ... a significant reduction in new or,enlarged gadolinium-enhancing lesions when ... active relapsing multiple,sclerosis (MS). These data will be presented ...

Cached Biology Technology:IsoTis Adjourns Special Meeting to October 23, 2007 2 IsoTis Adjourns Special Meeting to October 23, 2007 3 IsoTis Adjourns Special Meeting to October 23, 2007 4 CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 2 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 3 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 4 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 5 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 6

IsoTis Adjourns Special Meeting to October 23, 2007 CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy

(Date:6/18/2013)... , June 19, 2013 Paris Air Show ... Geotest-Marvin Test Systems) , a leading provider of ... industries, is demonstrating its solutions this week at ... 3-C82. With growing challenges including increasingly complex armament ... efficient, feature-rich, specialized aerospace test solutions that address ...

(Date:6/18/2013)... at the University of Calgary,s Faculty of Medicine have ... body from harmful bacteria. Platelets, a component of blood ... for specific bacteria, and upon detection, seal it off ... were published in Nature Immunology this week, ... immunity. , "The science community has known that platelets ...

(Date:6/18/2013)... Researchers from the United Kingdom, the Energy Department,s ... of Kentucky have recently published a paper describing ... borer Limnoria quadripunctata , commonly known as ... because they exhibit a relatively unique ability to ... microbes to break down the biomass they eat. ...

Breaking Biology News(10 mins):Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2 Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3 Immunity mechanism discovered 2 Novel enzyme from tiny gribble could prove a boon for biofuels research 2

[0] Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show [0] Immunity mechanism discovered [0] Novel enzyme from tiny gribble could prove a boon for biofuels research

... the growing demand from the public and the scientific ... Press has revised its copyright policy to allow authors ... three journals. The policy, which became effective May 1, ... Journal of Cell Biology, The Journal of Experimental Medicine ...

... the human genome has been sequenced, research into mechanism of ... most human genes have not been isolated. This is true ... protein kinases, which mediate the majority of signaling events in ... It has been estimated by systematic gene sequencing efforts that ...

... which he calls a "smarthroscope", may be able to ... could be useful in developing countries. It aims ... the tissue surrounding an area affected by illnesses such ... and bone damage. The instrument would also help ...

Cached Biology News:Rockefeller University Press allows authors to retain copyright to their published work 2 QUT researchers develop smart instrument for tissue damage assessment 2

Rockefeller University Press allows authors to retain copyright to their published work Researchers report the cloning of a key group of human genes, the protein kinases QUT researchers develop smart instrument for tissue damage assessment

... extends the legendary MSn performance of the ... information through Thermo Scientifics innovations in ion ... is the only mass spectrometer that offers ... Pulsed Q Collision Induced Dissociation (PQD) ...

... The reliable and compact GC-8A is ... applications. Economical and simple to use, the ... or flow control, on column injection port(s), ... ramp program models are available. The GC-8A ...

... system combines world-class performance hardware, Cerity Networked ... world-renowned support and columns, as well as ... that lets you reach uncompromising results and ... data. The Agilent 6820 GC system is ...

... new chapter to a 40-year ... 7890A GC gives you everything ... lab to the next level ... including advanced separation capabilities, powerful ...

Biology Products:

LTQ XL with ETD from Thermo Scientific GC-8 Gas Chromatograph from Shimadzu 6820 GC from Agilent Technologies 7890A GC from Agilent Technologies